From Yahoo Finance: 2025-05-24 08:45:00

Pfizer faces challenges with failed drug, tariffs, and political scrutiny, causing stock to drop over 60%. Despite setbacks, Pfizer remains financially strong with a promising pipeline. The low valuation offers potential for share price increase with modest success. Analysts weigh in on whether it’s time to buy the dip.

Pfizer’s pandemic success dwindled, leading to financial declines and stock price drops. Recent setbacks include the halt of a weight loss drug development and political pressures. Potential tariff policies and revenue hits add to the challenges. However, these issues are seen more as minor setbacks than fatal blows.

Although Pfizer’s recent struggles are concerning, the company maintains a solid financial foundation with a healthy pipeline. The stock’s low valuation may be underestimating its potential for growth. Investors could see significant returns with modest earnings growth and the company’s strong dividend yield.

Analysts suggest not overreacting to Pfizer’s challenges, as the company has a plan for cost savings and a solid financial position. The stock’s low valuation compared to its earnings guidance offers potential for market-beating returns. Pfizer may have the opportunity to outperform expectations with modest growth and valuation adjustments.

Read more: Down 63%, Should You Buy the Dip on Pfizer?